



Pediatric Cancer Research from Genetics and Morphology to Experimental Therapy

Guest Editor:

Prof. Dr. Atif Ahmed

1. Department of Laboratory
Medicine & Pathology, University
of Washington, Seattle, WA
98195, USA
2. Department of Pathology,
Seattle Children's Hospitals,
Seattle, WA 98105, USA

Deadline for manuscript
submissions:
closed (10 December 2024)

Message from the Guest Editor

Dear Colleagues,

Among the pediatric population (ages 0 to 19 years), the most common types of cancer are leukemias, followed by CNS tumors, lymphomas, neuroblastoma, kidney tumors, and malignant bone tumors. The incidence of pediatric tumors varies in different racial and ethnic groups, reflecting a biologic as well as an environmental basis for the ethnic disparity. Malignant tumors have a complex biology that is characterized by rapid proliferation, spectrum of cellular differentiation, and association with developmental genes. The genome is unique with a high prevalence of specific structural variations and predisposing germline variants. This unique genome translates to a unique morphology, microenvironment, and clinical behavior. Traditional and novel therapeutic regimens are burdened by therapy resistance and tumor progression. Genetic and epigenetic tumor sequencing has opened new opportunities for patients to be included in clinical trials. This Special Issue aims to highlight recent advances in pediatric tumor research, including pathology, tumor microenvironment, novel treatment, and cellular and genetic landscapes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)